SI3555076T1 - Novi derivati fenil propionske kisline in njihove uporabe - Google Patents

Novi derivati fenil propionske kisline in njihove uporabe

Info

Publication number
SI3555076T1
SI3555076T1 SI201731367T SI201731367T SI3555076T1 SI 3555076 T1 SI3555076 T1 SI 3555076T1 SI 201731367 T SI201731367 T SI 201731367T SI 201731367 T SI201731367 T SI 201731367T SI 3555076 T1 SI3555076 T1 SI 3555076T1
Authority
SI
Slovenia
Prior art keywords
propionic acid
new derivatives
phenyl propionic
phenyl
derivatives
Prior art date
Application number
SI201731367T
Other languages
English (en)
Slovenian (sl)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Kyung-Mi An
Chang-Hee Hong
Hyun-Jung Kwak
Shuo-Lin Cui
Hyo-Jung Song
Original Assignee
Il Dong Pharmaceutical Co., Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Dong Pharmaceutical Co., Ltd., filed Critical Il Dong Pharmaceutical Co., Ltd.,
Publication of SI3555076T1 publication Critical patent/SI3555076T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201731367T 2016-12-15 2017-12-14 Novi derivati fenil propionske kisline in njihove uporabe SI3555076T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160171541 2016-12-15
KR1020170171228A KR102007633B1 (ko) 2016-12-15 2017-12-13 신규 페닐 프로피온 산 유도체 및 이의 용도
EP17880872.1A EP3555076B1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof
PCT/KR2017/014757 WO2018111012A1 (en) 2016-12-15 2017-12-14 Novel phenyl propionic acid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
SI3555076T1 true SI3555076T1 (sl) 2023-09-29

Family

ID=62559593

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731367T SI3555076T1 (sl) 2016-12-15 2017-12-14 Novi derivati fenil propionske kisline in njihove uporabe

Country Status (22)

Country Link
US (2) US11225472B2 (https=)
EP (1) EP3555076B1 (https=)
JP (1) JP6892922B2 (https=)
KR (1) KR102007633B1 (https=)
CN (1) CN110049984B (https=)
AU (1) AU2017374460B2 (https=)
BR (1) BR112019012433A2 (https=)
CA (1) CA3042528C (https=)
DK (1) DK3555076T3 (https=)
ES (1) ES2948485T3 (https=)
FI (1) FI3555076T3 (https=)
HU (1) HUE062468T2 (https=)
IL (1) IL267239B (https=)
MX (1) MX2019007071A (https=)
MY (1) MY198292A (https=)
PH (1) PH12019501251A1 (https=)
PL (1) PL3555076T3 (https=)
PT (1) PT3555076T (https=)
RS (1) RS64259B1 (https=)
RU (1) RU2760266C2 (https=)
SI (1) SI3555076T1 (https=)
WO (1) WO2018111012A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
BR112023022114A2 (pt) * 2021-04-29 2024-01-30 Ildong Pharmaceutical Co Ltd Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2
WO2022269439A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
WO2023080299A1 (ko) * 2021-11-08 2023-05-11 일동제약(주) 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20240084229A (ko) * 2022-12-06 2024-06-13 유노비아 주식회사 안정성이 향상된 gpr40 효현제를 유효성분으로 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
JP5299810B2 (ja) * 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
US7786165B2 (en) * 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
CA2620476A1 (en) * 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
WO2007033002A1 (en) * 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JP5055852B2 (ja) 2006-06-21 2012-10-24 住友大阪セメント株式会社 鉄資源の回収方法
AR084050A1 (es) * 2010-12-01 2013-04-17 Boehringer Ingelheim Int Acidos indaniloxidihidrobenzofuranilaceticos
JP2013147443A (ja) * 2012-01-18 2013-08-01 Daiichi Sankyo Co Ltd β置換カルボン酸誘導体
US8633182B2 (en) * 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
WO2015044073A1 (en) * 2013-09-26 2015-04-02 Boehringer Ingelheim International Gmbh Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
WO2017180457A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Gpr40 agonists in anti-diabetic drug combinations
KR102007633B1 (ko) * 2016-12-15 2019-08-06 일동제약(주) 신규 페닐 프로피온 산 유도체 및 이의 용도
US20220112185A1 (en) * 2016-12-15 2022-04-14 Ildong Pharmaceutical Co., Ltd. Novel phenyl propionic acid derivatives and uses thereof
BR112023022114A2 (pt) * 2021-04-29 2024-01-30 Ildong Pharmaceutical Co Ltd Composto farmacêutico compreendendo agonista de gpr40 e inibidor de sglt-2
WO2022269439A1 (en) * 2021-06-21 2022-12-29 Ildong Pharmaceutical Co., Ltd. Method of controlling blood sugar level and treatment of diabetes and related conditions
US20230022803A1 (en) * 2021-06-25 2023-01-26 Ildong Pharmaceutical Co., Ltd. Novel crystalline form of gpr40 agonist

Also Published As

Publication number Publication date
PH12019501251A1 (en) 2019-12-11
CA3042528C (en) 2022-03-08
MY198292A (en) 2023-08-21
CA3042528A1 (en) 2018-06-21
CN110049984A (zh) 2019-07-23
AU2017374460B2 (en) 2020-08-20
IL267239B (en) 2022-07-01
EP3555076B1 (en) 2023-04-05
RU2760266C2 (ru) 2021-11-23
CN110049984B (zh) 2022-11-15
EP3555076A4 (en) 2019-10-23
DK3555076T3 (da) 2023-06-19
JP6892922B2 (ja) 2021-06-23
AU2017374460A1 (en) 2019-05-23
KR102007633B1 (ko) 2019-08-06
US20220064154A1 (en) 2022-03-03
BR112019012433A2 (pt) 2020-04-14
EP3555076A1 (en) 2019-10-23
RU2019121871A3 (https=) 2021-01-15
PL3555076T3 (pl) 2023-08-21
US20200223833A1 (en) 2020-07-16
PT3555076T (pt) 2023-06-30
RS64259B1 (sr) 2023-07-31
KR20180069718A (ko) 2018-06-25
JP2020502111A (ja) 2020-01-23
US11731961B2 (en) 2023-08-22
RU2019121871A (ru) 2021-01-15
ES2948485T3 (es) 2023-09-13
FI3555076T3 (fi) 2023-06-28
MX2019007071A (es) 2019-08-01
US11225472B2 (en) 2022-01-18
WO2018111012A1 (en) 2018-06-21
NZ753053A (en) 2021-01-29
HUE062468T2 (hu) 2023-11-28
IL267239A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
SI3555076T1 (sl) Novi derivati fenil propionske kisline in njihove uporabe
HRP20181742T1 (hr) Hidroksialkil-supstituirani derivati feniltriazola i njihova uporaba
IL289276A (en) Treprostinil derivatives and compositions and uses thereof
PL3212225T3 (pl) Sposoby i kompozycje zmodyfikowanych limfocytów t
IL255269A (en) Compositions of obeticholic acid and methods of use
SI3436048T1 (sl) Neoantigeni in načini uporabe
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
DK3663292T3 (da) Diphenylmethan-derivat i krystallinsk form
DK3328414T3 (da) Sammensætning til anvendelse i fremme af sårheling
SI3258962T1 (sl) Mešane sestave alergenov in postopki za njihovo uporabo
DK3182962T3 (da) Compositions and uses of amidine derivatives
SI3169328T1 (sl) Derivati kinolina za zdravljenje vnetnih bolezni
SI3240895T1 (sl) Sestavki in postopki za glikozilacijo proteinov
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
SI3262037T1 (sl) Novi derivati kinolina za uporabo v zdravljenju in preprečevanju virusnih okužb
SI3189074T1 (sl) Sestavki in postopki za zdravljenje in preprečevanje vnetja
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
SI3319948T1 (sl) Sestavki kalijevega acesulfama in postopek za izdelavo le-teh
IL256374B (en) Long-acting coagulation factors and methods of producing same
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3137873T3 (da) Viscometer and methods of use thereof
HUE045192T2 (hu) 6-morfolinil-2-pirazolil-9H-purin származékok és felhasználásuk PI3K inhibitorokként
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
DK3154528T3 (da) Sprøjtetørrede sammensætninger med forskellige opløsningsprofiler og fremgangsmåder til fremstilling deraf